Efficacy and safety of Solifenacin combined with Mirabegron in treating overactive bladder in female patients following bladder instillation for bladder cancer.

Abstract

Objective: To investigate the efficacy and safety of Solifenacin combined with Mirabegron in treating overactive bladder (OAB) in female patients following bladder instillation for bladder cancer.

Methods: A total of 62 female patients who developed OAB after undergoing transurethral resection of bladder tumor (TURBT) and subsequent intravesical chemotherapy with pirarubicin were enrolled from the Department of Urology at Guangzhou Twelfth People's Hospital. Patients were divided into two groups according to the method of treatment. The control group received Solifenacin, while the observation group received a combination of Solifenacin and Mirabegron. Pre- and post-treatment assessments included voiding frequency, Overactive Bladder Symptom Score (OABSS), urodynamic parameters, Incontinence Quality of Life (I-QOL) scores, and adverse reactions.

Results: Both groups showed a significant reduction in 24-hour voiding frequency and average nocturia after treatment (P<0.05), with the observation group exhibiting a more pronounced decrease compared to the control group (P<0.05). Post-treatment evaluations revealed lower OABSS and maximum detrusor pressure during the storage phase in both groups, along with an increase in the initial sensation of bladder filling volume and maximum bladder capacity (P<0.05). The observation group demonstrated more significant improvements in OABSS and maximum detrusor pressure during the storage phase, as well as higher initial bladder sensation volume and maximum bladder capacity compared to the control group (P<0.01).

Conclusion: The combination of Mirabegron and Solifenacin offers superior therapeutic effects in female patients with OAB following bladder instillation for bladder cancer, significantly improving patients' quality of life without adverse effects.